Navigation Links
Zentaris in Medical News

AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results

All amounts are in U.S. dollars QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ) ("the Company"), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three month...

AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prosta...

AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007

QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its third quarter 2007 financial and operating results before market open on Wednesday, November 7, 2007. Th...

AEterna's acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy

AEterna Laboratories Inc., a biopharmaceutical company focused on the development of novel therapeutic treatments in oncology and endocrinology recently acquired the new German based biopharmaceutical company, Zentaris AG. Following this acquisition// the new entity has in the pipeline six clinical...

Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System

...rship with sanofi-aventis in Korea and, moreover, have 20 other partners focusing on innovative products, including CSL, Solvay, Actelion, and AEterna zentaris among others. HANDOK is the leader in diabetes treatment in Korea. It is also known to have leading expertise in various therapeutic categories includ...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...ling Technologies Index (HHV) Drop Hillenbrand Industries (NYSE: HB ) Add Eurand N.V. (Nasdaq: EURX ) GI/Gender Index (HHU) Drop AEterna zentaris (Nasdaq: AEZS ) King Pharmaceuticals (NYSE: KG ) Nastech Pharmaceutical (Nasdaq: NSTK ) Add Columbia Laboratories Inc. (Nasdaq: CBRX ) Ei...

Memory Pharmaceuticals Appoints Paul Blake to Board of Directors

... Dr. Blake has over 27 years of clinical development experience. He currently serves as the Senior Vice President and Chief Medical Officer of AEterna zentaris Inc., a bio-pharmaceutical company. Previously, Dr. Blake was Senior Vice President, Clinical Research and Development for Avigenics Inc. From 2001 to...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...1595.9 ALIZYME PLC AZM LN 2792758976 AETERNA zentaris INC AEZS 1788995095 King Pharmaceuticals ...32238 Geron Corp GERN 159494102.8 AETERNA zentaris INC AEZS 733256362.2 Telik Inc ...
Zentaris in Medical Technology

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in ovarian cancer with A...

AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial

Cetrorelix showed good safety and tolerability profile Reduction of testosterone concentration was maintained above castration level Japanese partner Shionogi initiates Phase 2b trial QUEBEC CITY, March 22, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. along with its Japanese partner Shionog...

AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on i...

AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatment of early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract...

terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment QUBEC CITY, Canada, April 16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company foc...

AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx B...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...cutive Officer. New Board Member. In November 2007, Paul Blake, M.B., currently Senior Vice President and Chief Medical Officer of AEterna zentaris Inc., joined Memory Pharmaceuticals' Board of Directors. Dr. Blake has over 27 years of clinical development experience, including pre...

Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie

... were well tolerated. About Ozarelix and Development Alliance with AEterna zentaris Ozarelix is a fourth generation Luteinizing Hormone Releasing Hormone (LHR...ection. In August 2004, Spectrum received an exclusive license from AEterna zentaris to develop and market ozarelix for all potential indications in North Ameri...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

...ne Releasing Hormone (LHRH) antagonist administered as an intramuscular injection. In August 2004, Spectrum received an exclusive license from AEterna zentaris to develop and market ozarelix for all potential indications in North America (including Canada and Mexico) and India. In addition, Spectrum will re...

More>>

Zentaris in Biological Technology

AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference

QUEBEC CITY, Aug. 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its President and CEO, Juergen Engel, Ph.D., will present a corporate overview at the upcoming Canaccor...

AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009

QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its second quarter 2009 financial and operating results before market open on Tuesday, August 11, 2009. The Co...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

AEterna Zentaris Receives US$10 Million from Institutional Investors

QUEBEC CITY, June 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, announced today that it has completed its previously announced registered direct offering of US$10 million of units compris...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today disclosed preliminary results for the Company's European multi-center Phase 2 trial in non-small cell lung cancer (NSC...

AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130

All amounts are in US dollars QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that after regaining from Ardana Biosciences Ltd. ("Ardana"), the worldwid...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AE...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting ...
Other Tags
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... has joined the company as the new Global Communications Director for InHealth Media. ... relations experience having spent the last 16 years doing on-air television, producing shows, ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Next weekend is ... summer (which astronomically, officially ends on September 22nd this year). For IT security personnel, ... hangovers linger on which could prove far more costly than a simple headache. , ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
Other Contents